Vaccine manufacturing: challenges and solutions

被引:260
作者
Ulmer, Jeffrey B.
Valley, Ulrich
Rappuoli, Rino
机构
[1] Novartis Vaccines & Diagnost, Emeryville, CA 94608 USA
[2] GMBH & Co KG, Novartis Vaccines & Diagnost, D-35041 Marburg, Germany
[3] Novartis Vaccines & Diagnost SRL, I-53100 Siena, Italy
关键词
D O I
10.1038/nbt1261
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The recent influenza vaccine shortages have provided a timely reminder of the tenuous nature of the world's vaccine supply and the potential for manufacturing issues to severely disrupt vital access to important vaccines. The application of new technologies to the discovery, assessment, development and production of vaccines has the potential to prevent such occurrences and enable the introduction of new vaccines. Gene- based vaccines, virus- like particles, plant- derived vaccines and novel adjuvants and delivery systems represent promising approaches to creating safer, more potent vaccines. As a consequence, more people will have faster access to more effective vaccines against a broader spectrum of infectious diseases. However, the increased cost of producing new vaccines and regulatory uncertainty remain challenges for vaccine manufacturers.
引用
收藏
页码:1377 / 1383
页数:7
相关论文
共 36 条
  • [1] Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children:: single-blind extended follow-up of a randomised controlled trial
    Alonso, PL
    Sacarlal, J
    Aponte, JJ
    Leach, A
    Macete, E
    Aide, P
    Sigauque, B
    Milman, J
    Mandomando, I
    Bassat, Q
    Guinovart, C
    Espasa, M
    Corachan, S
    Lievens, M
    Navia, MM
    Dubois, MC
    Menendez, C
    Dubovsky, F
    Cohen, J
    Thompson, R
    Ballou, WR
    [J]. LANCET, 2005, 366 (9502) : 2012 - 2018
  • [2] Belshe Robert, 2004, Expert Rev Vaccines, V3, P643, DOI 10.1586/14760584.3.6.643
  • [3] Genetic stability of live, cold-adapted influenza virus components of the FluMist®/CAIV-T vaccine throughout the manufacturing process
    Buonagurio, DA
    Bechert, TM
    Yang, CF
    Shutyak, L
    D'Arco, GA
    Kazachkov, Y
    Wang, HP
    Rojas, EA
    O'Neill, RE
    Spaete, RR
    Coelingh, KL
    Zamb, TJ
    Sidhu, MS
    Udem, SA
    [J]. VACCINE, 2006, 24 (12) : 2151 - 2160
  • [4] CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B® HBV vaccine in healthy adults:: A double-blind phase I/II study
    Cooper, CL
    Davis, HL
    Morris, ML
    Efler, SM
    Al Adhami, M
    Krieg, AM
    Cameron, DW
    Heathcote, J
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2004, 24 (06) : 693 - 701
  • [5] Medicine at the medical center then and now: One hundred years of progress
    Cooper, MR
    Stewart, DC
    Kahl, FR
    Brown, WM
    Cordell, AR
    [J]. SOUTHERN MEDICAL JOURNAL, 2002, 95 (10) : 1113 - 1121
  • [6] DNA vaccines
    Donnelly, JJ
    Ulmer, JB
    Shiver, JW
    Liu, MA
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 : 617 - 648
  • [7] Farchaus JW, 1998, APPL ENVIRON MICROB, V64, P982
  • [8] Mitigation strategies for pandemic influenza in the United States
    Germann, TC
    Kadau, K
    Longini, IM
    Macken, CA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (15) : 5935 - 5940
  • [9] Key drivers behind the development of global vaccine market
    Gréco, M
    [J]. VACCINE, 2001, 19 (13-14) : 1606 - 1610
  • [10] Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children
    Halperin, SA
    Smith, B
    Mabrouk, T
    Germain, M
    Trépanier, P
    Hassell, T
    Treanor, J
    Gauthier, R
    Mills, EL
    [J]. VACCINE, 2002, 20 (7-8) : 1240 - 1247